Evozyne vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Evozyne applies generative AI and evolutionary principles to design novel therapeutic proteins; raised $144M total including $81M Series B led by Fidelity and OrbiMed with NVIDIA NVentures participation; 54 employees; Chicago-based.
About
Evozyne is a Chicago-based biotechnology company founded in 2020 by Andrew Ferguson and Rama Ranganathan that uses generative AI to design novel, high-performance proteins for therapeutic and commercial applications. The company occupies a distinctive position at the frontier of AI-driven drug discovery: unlike companies that apply AI to screen existing molecule libraries or predict protein folding (like AlphaFold), Evozyne generates entirely new protein sequences from scratch using its proprietary understanding of evolutionary sequence-function relationships. These de novo proteins are designed with specific functional properties for therapeutic development or industrial applications.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.